Opinion
Volume 07:04, 2025

Journal of Surgical Pathology and Diagnosis

ISSN: 2684-4575

Open Access

Ancillary Testing: Diverse Applications, Precise Outcomes

Beatrice Ndidika*

Department of Cytopathology \& Surgical Systems, Niger Delta University of Medical Research, Port Leon, Nigeria

Introduction

This review highlights the critical role of ancillary testing, including immunohistochemistry and molecular diagnostics, in refining the diagnosis and classification of central nervous system tumors. It emphasizes how these tests move beyond traditional histopathology to provide precision, especially with the evolving WHO classifications, ensuring more accurate prognostication and personalized treatment strategies [1].

This multicenter study demonstrates how ancillary tests significantly aid in diagnosing problematic melanocytic lesions, especially when standard histopathology is inconclusive. The findings confirm that integrating molecular and immunohistochemical markers improves diagnostic accuracy, thereby reducing ambiguity and guiding appropriate patient management [2].

This article explores the growing impact of molecular ancillary testing in diagnosing infectious diseases, emphasizing its ability to provide rapid, sensitive, and specific pathogen identification. It discusses how these advanced techniques complement traditional culture methods, leading to quicker treatment decisions and improved patient outcomes, particularly in critical care settings [3].

This article provides an insightful overview of quality assurance practices concerning ancillary testing in anatomic pathology. It underscores the necessity of rigorous protocols, from pre-analytical to post-analytical phases, to ensure the reliability and accuracy of these advanced tests. Maintaining high standards here is crucial for accurate diagnoses and patient safety [4].

This review delves into the significant potential of liquid biopsy as an ancillary test in oncology, not just for initial cancer diagnosis but also for disease monitoring and recurrence detection. It highlights how analyzing circulating tumor DNA and other biomarkers from blood samples offers a less invasive alternative, improving treatment stratification and patient management [5].

This review discusses the vital role of ancillary testing in the precise diagnosis and ongoing monitoring of systemic autoimmune diseases. It highlights the importance of specific autoantibody panels and other biomarkers in differentiating various autoimmune conditions, tracking disease activity, and predicting treatment response, which ultimately personalizes patient care [6].

This article investigates the clinical utility and implementation hurdles of pharmacogenomic ancillary testing in guiding medication therapy. It explains how genetic insights can personalize drug selection and dosing, minimizing adverse effects and optimizing treatment efficacy. The discussion also covers the practical challenges of integrating this testing into routine clinical practice [7].

This systematic review assesses the utility of point-of-care ancillary tests in diagnosing acute respiratory infections. It highlights their potential for rapid, on-site pathogen detection, which can significantly shorten diagnostic turnaround times and enable timely intervention, especially valuable in resource-limited settings or during outbreaks [8].

This article reviews the current state and future prospects of newborn screening and ancillary testing for genetic disorders. It highlights how expanded screening panels, combined with advanced molecular diagnostics, facilitate early detection of a broader range of conditions. This early identification is crucial for prompt intervention, which can dramatically improve developmental outcomes for affected infants [9].

This article explores the growing importance of biomarkers as ancillary tests for diagnosing and prognosticating neurodegenerative diseases. It discusses how cerebrospinal fluid, blood, and imaging biomarkers are enhancing diagnostic accuracy and allowing for earlier intervention and more precise patient stratification in conditions like Alzheimer's and Parkinson's [10].

Description

Ancillary testing has fundamentally transformed diagnostic medicine, offering unparalleled precision and depth beyond traditional histopathology. In the realm of central nervous system tumors, for example, immunohistochemistry and molecular diagnostics are critical for refining diagnoses and classifications, ensuring more accurate prognostication and guiding personalized treatment strategies in line with evolving WHO classifications [1]. This precision extends to challenging cases such as problematic melanocytic lesions, where ancillary tests, by integrating molecular and immunohistochemical markers, significantly improve diagnostic accuracy, reduce ambiguity, and guide appropriate patient management when standard histopathology proves inconclusive [2]. Beyond specific disease types, molecular ancillary testing is also making a substantial impact in diagnosing infectious diseases, providing rapid, sensitive, and specific pathogen identification. These advanced techniques effectively complement traditional culture methods, leading to quicker treatment decisions and improved patient outcomes, especially in critical care settings where time is of the essence [3].

The utility of ancillary testing spans a wide spectrum of medical applications, revolutionizing how complex diseases are approached. In oncology, liquid biopsy stands out as a promising ancillary test. It offers a less invasive alternative for initial cancer diagnosis, disease monitoring, and the detection of recurrence by analyzing circulating tumor DNA and other biomarkers from blood samples. This

innovative approach significantly improves treatment stratification and overall patient management [5]. Similarly, in systemic autoimmune diseases, specific autoantibody panels and other biomarkers are indispensable. They play a vital role in differentiating various autoimmune conditions, tracking disease activity over time, and predicting treatment responses, leading to highly personalized patient care strategies [6]. The application of biomarkers also extends to neurodegenerative diseases, where cerebrospinal fluid, blood, and imaging biomarkers are crucial ancillary tests. They enhance diagnostic accuracy and enable earlier intervention and more precise patient stratification in conditions like Alzheimer's and Parkinson's, offering new avenues for managing these complex disorders [10].

Moreover, ancillary testing is pivotal in personalizing medicine and improving public health diagnostics. Pharmacogenomic ancillary testing, for instance, investigates clinical utility in guiding medication therapy by leveraging genetic insights. This approach personalizes drug selection and dosing, effectively minimizing adverse effects while optimizing treatment efficacy. However, integrating this testing into routine clinical practice presents practical challenges that need careful consideration [7]. In acute care settings, point-of-care ancillary tests are invaluable for diagnosing acute respiratory infections. Their ability to provide rapid, on-site pathogen detection substantially shortens diagnostic turnaround times, allowing for timely interventions. This is particularly crucial in resource-limited environments or during infectious disease outbreaks, where speed can save lives [8]. Furthermore, newborn screening programs are being expanded with ancillary testing for genetic disorders. Combining expanded screening panels with advanced molecular diagnostics facilitates the early detection of a broader range of conditions, which is crucial for prompt intervention and dramatically improved developmental outcomes for affected infants [9].

For ancillary testing to deliver on its immense potential, rigorous quality assurance practices are absolutely paramount. An overview of quality assurance in anatomic pathology highlights the necessity of stringent protocols across all phases, from pre-analytical to post-analytical, to ensure the reliability and accuracy of these advanced tests [4]. Maintaining consistently high standards in these processes is not merely a matter of best practice; it is fundamental for accurate diagnoses and, ultimately, for ensuring patient safety and trust in medical interventions. The implementation challenges for some of these tests, such as pharmacogenomic testing, underscore the ongoing need for research into effective integration strategies and standardization to fully realize the benefits of these powerful diagnostic tools [7].

Conclusion

The provided data highlights the widespread and critical role of ancillary testing across diverse medical specialties, moving beyond conventional histopathology to achieve greater precision in diagnosis, classification, prognostication, and treatment personalization. This includes the essential application of immunohistochemistry and molecular diagnostics for central nervous system tumors, refining diagnoses according to evolving World Health Organization (WHO) classifications. Similarly, these advanced tests significantly aid in diagnosing challenging melanocytic lesions, providing clarity when standard methods are inconclusive. In infectious diseases, molecular ancillary testing offers rapid, sensitive, and specific pathogen identification, complementing traditional culture techniques for quicker treatment decisions.

The scope of ancillary testing extends to emerging fields like liquid biopsy in oncology, offering a less invasive approach for cancer diagnosis, monitoring, and recurrence detection by analyzing circulating tumor DNA. For systemic autoimmune diseases, specific autoantibody panels and biomarkers are crucial for differentiating conditions, tracking activity, and predicting treatment response. Pharmacogenomic testing guides personalized medication therapy, optimizing drug selection and dosing while minimizing adverse effects. Point-of-care tests are transforming acute respiratory infection diagnostics with rapid, on-site pathogen detection, particularly beneficial in resource-limited settings. Furthermore, expanded newborn screening panels, coupled with advanced molecular diagnostics, facilitate early detection of genetic disorders, improving developmental outcomes. Even in neurodegenerative diseases, cerebrospinal fluid, blood, and imaging biomarkers are vital for neurodegenerative disease diagnosis and prognosis. Underlying the success of these varied applications is the critical need for rigorous quality assurance practices in anatomic pathology, ensuring the reliability and accuracy essential for patient safety.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Rakesh Kumar, Gursimran Singh, Amit Jain, Nidhi Gupta, Praveen Kumar, Vishal Singh. "The role of ancillary testing in the accurate diagnosis and classification of CNS tumors: A review." *Brain Tumor Res Treat* 11 (2023):1-13.

2. Joan Guitart, Christian Querfeld, Matthew T. Tetzlaff, Meera L. Salama, Jessica S. Poling, Ncoza P. Khumalo. "Utility of Ancillary Tests in Challenging Cases of Melanocytic Lesions: A Multicenter Study." *Am J Dermatopathol* 43 (2021):251-259.

3. Benjamin A. Pinsky, Preeti Ramanan, Chinnambigai Maruthachalam, Alan Tan, Preetish Singh, Eunyoung Kim. "The expanding role of molecular ancillary testing in the diagnosis of infectious diseases." *J Clin Microbiol* 58 (2020):e00780-20.

4. Maria Margarita Tretiakova, Ravi Salgia, Mike Parilla, Kirti Vani, Luanne Chen, Philip Gattuso. "Quality Assurance in Anatomic Pathology: An Overview of Ancillary Testing." *Arch Pathol Lab Med* 144 (2020):59-71.

5. Dhia Al-Hafidh, Safaa Al-Salihi, Ruqaya Al-Fadhli, Muthanna Al-Kuraishi, Ali Al-Attar, Ali Al-Marashdi. "Liquid Biopsy as an Ancillary Test for Cancer Diagnosis and Monitoring: A Review." *Med Sci Monit* 28 (2022):e937965.

6. Carlo Selmi, Annarosa Lleo, Marta E. Alarcon-Riquelme, M. Eric Gershwin. "The role of ancillary testing in the diagnosis and monitoring of systemic autoimmune diseases." *Autoimmun Rev* 19 (2020):102486.

7. Jason H. Karnes, Alan R. Shuldiner, Cynthia R. Lee, Johnson JA, Gammal RS, Caudle KE. "Pharmacogenomic Ancillary Testing: Clinical Utility and Implementation Challenges." *Clin Pharmacol Ther* 109 (2021):1475-1488.

8. Soyoung Lee, Jaewook S. Lee, Sangyoon Kim, Kye-Hyung Park, Hongbin Kim, Joon Young Choi. "Point-of-Care Ancillary Tests for Diagnosing Acute Respiratory Infections: A Systematic Review." *J Korean Med Sci* 37 (2022):e167.

9. Anne Marie Comeau, Diane M. Kay, Rani H. Singh, Harvey L. Levy, Julie Bodkin, Hylke De Walle. "Newborn Screening and Ancillary Testing for Genetic Disorders: Current Landscape and Future Directions." *Clin Perinatol* 47 (2020):29-45.

10. Harald Hampel, Andrea Vergallo, Kaj Blennow, Henrik Zetterberg, Andrea Leuzy, Bruno Dubois. "Biomarkers as Ancillary Tests in the Diagnosis and Prognosis of Neurodegenerative Diseases." *Neurobiol Aging* 79 (2019):172-184.

How to cite this article: Ndidika, Beatrice. "Ancillary Testing: Diverse Applications, Precise Outcomes." *J Surg Path Diag* 07 (2025):35.

Address for Correspondence: Beatrice, Ndidika, Department of Cytopathology \& Surgical Systems, Niger Delta University of Medical Research, Port Leon, Nigeria , E-mail: b.ndidika@ndumr.ng

Received: 02-Nov-2025, Manuscript No. jspd-25-174871; **Editor assigned:** 04-Nov-2025, PreQC No. P-174871; **Reviewed:** 18-Nov-2025, QC No. Q-174871; **Revised:** 24-Nov-2025, Manuscript No. R-174871; **Published:** 29-Nov-2025, DOI: 10.37421/2684-4575.2025.6.035